Renovaro Appoints Nathen Fuentes as Chief Financial OfficerSenior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives
Renovaro Issues Shareholder Letter and Provides Corporate UpdateCompany to Host International Roadshow the Week of January 13, 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Predictive Oncology Inc. (Nasdaq - POAI), SunLink Health Systems, Inc. (NYSE American - SSY), Universal Stainless & Alloy Products, Inc. (Nasdaq - USAP), PattersonBALA CYNWYD, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Renovaro to Acquire Predictive Oncology in All-Stock TransactionAcquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data
Predictive Oncology Announces Agreement to be Acquired by Renovaro- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications –
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BVCurrent Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding ProgramLUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI
Renovaro Regains Compliance with NASDAQ Listing RequirementLOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (
NASDAQRENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule, 5550(a)(2). The Company’s security will continue to be listed and traded on The Nasdaq Stock Market and this matter is now closed.
Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease DetectionRenovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions
Renovaro Issues Shareholder Letter and Provides Corporate UpdateLOS ANGELES, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (
NASDAQRENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein.
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore SequencingAMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (
NASDAQRENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024.
Renovaro Announces Strategic Restructuring and Leadership TransitionLOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (
NASDAQRENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company’s AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD.
PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care DiagnosticsStrategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes
Specialist AI Team from “PersonalAIze” Highlights the Strength, Potential and Visionary Talent Behind Software as a Service (SaaS) Platform for Early Cancer Detection: Renovaro, Inc. (Nasdaq: RENB)Renovaro, Inc. (Nasdaq: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer DetectionAssessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology CongressAMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (
NASDAQRENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.
